Hi ForrestG, What were you impressions of the progress reported for the Leishmaniasis product? One of the slides metions a new atigen formulation, implying that the original one was not effective enough. Was there any more discussion of this point? Also were there any questions about new products such as for Lyme disease?
Although QFT-TB Gold and IT have additional patents, I note that the BASE Quantiferon technology platform patent starts to expire next year (Canada) and I wonder if this may be a reason why there has been little R&D development in recent years (excluding the TB products.)
CST Price at posting:
$2.01 Sentiment: Hold Disclosure: Held
